Skip to content

Clinical Efficacy of Tongluo Xiaoban Formula in Treating Carotid Atherosclerotic Plaques

Clinical Efficacy of Tongluo Xiaoban Formula in Treating Carotid Atherosclerotic Plaques

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001700
Enrollment
Unknown
Registered
2025-09-11
Start date
2023-05-01
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid atherosclerotic plaque

Interventions

Lifestyle Intervention Group:Healthy Lifestyle Intervention
Herbal Compound Formula Intervention Group:Lifestyle Intervention Supplemented with Herbal Compound Formula Treatment

Sponsors

Jinan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: (1) those who met the diagnostic standard of soft plaques in carotid atherosclerotic plaques by carotid ultrasonography and did not take relevant medication within the last 1 week; (2) aged 18 years = age = 55 years and the sex was not limited; (3) CT examination excluded intracranial organic lesions; (4) Never undergone stent implantation for related diseases; (5) Regular work and rest and regular diet during the clinical study; (6) Informed consent signed by the patient himself/herself or on behalf of his/her immediate family members; (7) Smoking and alcohol cessation are required during the study. (Note: Patients who meet the above conditions at the same time can be included in this study).

Exclusion criteria

Exclusion criteria: (1) non-carotid atherosclerotic plaque soft spot diagnosis or patients who have recently taken relevant drug therapy; (2) age 55 years old; (3) suffering from severe intracranial organic lesions; (4) stent implantation treatment for related diseases; (5) during the clinical study period irregular work and rest and diet; (6) Patients or family members who refuse to accept the treatment plan; (7) Patients who are unconscious unable to express the subjective symptoms of discomfort or accompanied by severe depression anxiety symptoms psychiatric patients; (8) Progressive malignant tumors or other serious consumptive diseases prone to combining with infections and hemorrhage; (9) Combined with cardiovascular hepatic renal gastrointestinal hematopoietic system and other primary diseases; (10) Pregnant and breastfeeding women; (11) Allergies. (Note: Patients who meet any of the above criteria are excluded.)

Design outcomes

Primary

MeasureTime frame
Maximum Cross-sectional Thickness of Carotid Atherosclerotic Plaque;

Secondary

MeasureTime frame
Carotid Intima-Media Thickness;Percentage of Carotid Artery Area Stenosis;Blood Lipid Levels;

Countries

China

Contacts

Public ContactXiaoliang Li

Jinan Hospital

doctorlixiaoliang@163.com15269195950

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026